Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32238417,Clint,"Though Vmax and Km varied widely among CYP2B6 variants, stereoselectivity was preserved, reflected by similar Clint(S,S-hydroxybupropion)/Clint(R,R-hydroxybupropion) ratios (1.8-2.9), except CYP2B6.17, which was less enantioselective.",Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238417/),,1.8-2.9,938,DB01156,Bupropion
,27495292,fm,"The fm,CYP2B6 was predicted to be 21%, and the fm,CYP2C19, 6% for racemic bupropion.","Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27495292/),%,21,2266,DB01156,Bupropion
,27495292,fm,"The fm,CYP2B6 was predicted to be 21%, and the fm,CYP2C19, 6% for racemic bupropion.","Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27495292/),%,6,2267,DB01156,Bupropion
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,8.79,5916,DB01156,Bupropion
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,20.17,5917,DB01156,Bupropion
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,16.18,5918,DB01156,Bupropion
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,17.66,5919,DB01156,Bupropion
,27518170,Cmax,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],226,12854,DB01156,Bupropion
,27518170,Cmax,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],386,12855,DB01156,Bupropion
,27518170,AUC0-∞,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],1580,12856,DB01156,Bupropion
,27518170,AUC0-∞,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],8060,12857,DB01156,Bupropion
,27518170,Cmax,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],707,12858,DB01156,Bupropion
,27518170,AUC0-∞,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],212,12859,DB01156,Bupropion
,27518170,AUC0-∞,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],5750,12860,DB01156,Bupropion
,27518170,AUC0-∞,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],3860,12861,DB01156,Bupropion
,6436464,absolute recovery,The method provides an absolute recovery of approximately 85% for bupropion and approximately 98% for the metabolites.,Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436464/),%,85,20141,DB01156,Bupropion
,6436464,absolute recovery,The method provides an absolute recovery of approximately 85% for bupropion and approximately 98% for the metabolites.,Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436464/),%,98,20142,DB01156,Bupropion
,6436464,detection limits,The detection limits were approximately 5 ng/mL for bupropion and 100 ng/mL for the major metabolites.,Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436464/),[ng] / [ml],5,20143,DB01156,Bupropion
,6436464,detection limits,The detection limits were approximately 5 ng/mL for bupropion and 100 ng/mL for the major metabolites.,Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436464/),[ng] / [ml],100,20144,DB01156,Bupropion
,32215046,flow rate,"The chromatographic separation was performed on a Waters XBridge™ C18 column (2.1 mm × 100 mm, 3.5 μm) using a gradient elution with the mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.",HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32215046/),[ml] / [min],0.3,20924,DB01156,Bupropion
,20642555,K(i),"Two terpenoids, borneol and isoborneol, are major constituents of woohwangcheongsimwon suspension, and show a competitive inhibition of CYP2B6 with K(i) values of 9.5 and 5.9 microM, respectively.","Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642555/),μM,9.5,22902,DB01156,Bupropion
,20642555,K(i),"Two terpenoids, borneol and isoborneol, are major constituents of woohwangcheongsimwon suspension, and show a competitive inhibition of CYP2B6 with K(i) values of 9.5 and 5.9 microM, respectively.","Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642555/),μM,5.9,22903,DB01156,Bupropion
,26232561,flow rate,"Chromatographic separation was performed on hydro-RP column (75×2.0mm, 80Å, 4μm) with isocratic elution using 5mM ammonium formate buffer/acetonitrile (30:70, v/v) at a flow rate of 0.4mL/min and the total run time was 5min.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),[ml] / [min],0.4,26600,DB01156,Bupropion
,26232561,total run time,"Chromatographic separation was performed on hydro-RP column (75×2.0mm, 80Å, 4μm) with isocratic elution using 5mM ammonium formate buffer/acetonitrile (30:70, v/v) at a flow rate of 0.4mL/min and the total run time was 5min.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),min,5,26601,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,663.2,26602,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,331.0,26603,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,687.2,26604,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,587.3,26605,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,293.1,26606,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,563.3,26607,DB01156,Bupropion
,26232561,m/,"The ion transitions monitored were m/z 663.2→331.0, 687.2→343.1, 587.3→293.1, 563.3→281.0, and 240.0→184.0 for PsA, PsA 107, PsA 109, PsA 123, and IS, respectively.",Determination and validation of psammaplin A and its derivatives in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26232561/),,240.0,26608,DB01156,Bupropion
,3931955,elimination t1/2,"The mean elimination t1/2 values of BUP, TB, EB, and HB were 9.8, 19.8, 26.8, and 22.2 hours, respectively.",Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3931955/),h,9.8,27647,DB01156,Bupropion
,3931955,elimination t1/2,"The mean elimination t1/2 values of BUP, TB, EB, and HB were 9.8, 19.8, 26.8, and 22.2 hours, respectively.",Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3931955/),h,19.8,27648,DB01156,Bupropion
,3931955,elimination t1/2,"The mean elimination t1/2 values of BUP, TB, EB, and HB were 9.8, 19.8, 26.8, and 22.2 hours, respectively.",Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3931955/),h,26.8,27649,DB01156,Bupropion
,3931955,elimination t1/2,"The mean elimination t1/2 values of BUP, TB, EB, and HB were 9.8, 19.8, 26.8, and 22.2 hours, respectively.",Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3931955/),h,22.2,27650,DB01156,Bupropion
,2124217,elimination half-life,The mean elimination half-life of the morpholinol metabolite was significantly prolonged in subjects with alcoholic liver disease (32.2 +/- 13.5 vs.,Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124217/),,32.2,27665,DB01156,Bupropion
,32648334,AUC0-24,"After multiple-dose administration of upadacitinib 30 mg once daily, upadacitinib mean ± SD AUC0-24 was 641 ± 177 ng·h/mL, and Cmax was 83.3 ± 30.7 ng/mL.","Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32648334/),[h·ng] / [ml],641,30490,DB01156,Bupropion
,32648334,Cmax,"After multiple-dose administration of upadacitinib 30 mg once daily, upadacitinib mean ± SD AUC0-24 was 641 ± 177 ng·h/mL, and Cmax was 83.3 ± 30.7 ng/mL.","Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32648334/),[ng] / [ml],83.3,30491,DB01156,Bupropion
,20230334,peak concentration,The peak concentration was 1.114 mg/L.,Bupropion toxicokinetic: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230334/),[mg] / [l],1.114,30596,DB01156,Bupropion
,20230334,T(max),"The observed T(max) was found to be 8.25 h, the calculated alpha half-life 10.9 h (+/-SE of 4.47%), and the calculated beta half-life 19.8 h (+/-SE 12.62%).",Bupropion toxicokinetic: a case report. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230334/),h,8.25,30597,DB01156,Bupropion
,20230334,alpha half-life,"The observed T(max) was found to be 8.25 h, the calculated alpha half-life 10.9 h (+/-SE of 4.47%), and the calculated beta half-life 19.8 h (+/-SE 12.62%).",Bupropion toxicokinetic: a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230334/),h,10.9,30598,DB01156,Bupropion
,20230334,beta half-life,"The observed T(max) was found to be 8.25 h, the calculated alpha half-life 10.9 h (+/-SE of 4.47%), and the calculated beta half-life 19.8 h (+/-SE 12.62%).",Bupropion toxicokinetic: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230334/),h,19.8,30599,DB01156,Bupropion
,18321686,equivalent steady state plasma concentrations,6-Beta-naltrexol equivalent steady state plasma concentrations of 6.4 ng/ml were obtained after application of the codrug as compared to 1.2 ng/ml from 6-beta-naltrexol base.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],6.4,32584,DB01156,Bupropion
,18321686,equivalent steady state plasma concentrations,6-Beta-naltrexol equivalent steady state plasma concentrations of 6.4 ng/ml were obtained after application of the codrug as compared to 1.2 ng/ml from 6-beta-naltrexol base.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],1.2,32585,DB01156,Bupropion
,18321686,steady state plasma concentration,The steady state plasma concentration of hydroxybupropion after codrug application was 6.9 ng/ml.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],6.9,32586,DB01156,Bupropion
,1876622,half-life,"Fluoxetine distinguishes itself in that its half-life is 2 to 3 days, whereas the mean half-life of buproprion and the tricyclics are 10 to 14 hours.",Treatment of depression. New pharmacologic approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1876622/),d,2 to 3,37731,DB01156,Bupropion
,1876622,half-life,"Fluoxetine distinguishes itself in that its half-life is 2 to 3 days, whereas the mean half-life of buproprion and the tricyclics are 10 to 14 hours.",Treatment of depression. New pharmacologic approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1876622/),h,10 to 14,37732,DB01156,Bupropion
,27723114,mass-to-charge (m/z) ratios,"Two non-reported metabolites (M1 and M3) were identified with mass-to-charge (m/z) ratios of 276 (M1, hydration of bupropion) and 258 (M3, hydroxylation of threo/erythrohydrobupropion) from human plasma in addition to the known hydroxybupropion, threo/erythrohydrobupropion and the glucuronidation products of the major metabolites (M2 and M4-M7).",Identification of non-reported bupropion metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27723114/),,276,40042,DB01156,Bupropion
,27723114,mass-to-charge (m/z) ratios,"Two non-reported metabolites (M1 and M3) were identified with mass-to-charge (m/z) ratios of 276 (M1, hydration of bupropion) and 258 (M3, hydroxylation of threo/erythrohydrobupropion) from human plasma in addition to the known hydroxybupropion, threo/erythrohydrobupropion and the glucuronidation products of the major metabolites (M2 and M4-M7).",Identification of non-reported bupropion metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27723114/),,258,40043,DB01156,Bupropion
,30520001,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The geometric mean of the bupropion area under the concentration-time curve from 0 to 24 h (AUC0-24) was 498.2 and 1,165.7 h·ng/mL on days 1 and 14, respectively; maximum plasma concentration (Cmax) was 49.9 ng/mL on day 1 and steady-state maximum observed plasma concentration (Css_max) was 111.9 ng/mL on day 14.","Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520001/),[h·ng] / [ml],498.2,55020,DB01156,Bupropion
,30520001,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The geometric mean of the bupropion area under the concentration-time curve from 0 to 24 h (AUC0-24) was 498.2 and 1,165.7 h·ng/mL on days 1 and 14, respectively; maximum plasma concentration (Cmax) was 49.9 ng/mL on day 1 and steady-state maximum observed plasma concentration (Css_max) was 111.9 ng/mL on day 14.","Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520001/),[h·ng] / [ml],"1,165.7",55021,DB01156,Bupropion
,30520001,maximum plasma concentration (Cmax),"The geometric mean of the bupropion area under the concentration-time curve from 0 to 24 h (AUC0-24) was 498.2 and 1,165.7 h·ng/mL on days 1 and 14, respectively; maximum plasma concentration (Cmax) was 49.9 ng/mL on day 1 and steady-state maximum observed plasma concentration (Css_max) was 111.9 ng/mL on day 14.","Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520001/),[ng] / [ml],49.9,55022,DB01156,Bupropion
,30520001,steady-state maximum observed plasma concentration (Css_max),"The geometric mean of the bupropion area under the concentration-time curve from 0 to 24 h (AUC0-24) was 498.2 and 1,165.7 h·ng/mL on days 1 and 14, respectively; maximum plasma concentration (Cmax) was 49.9 ng/mL on day 1 and steady-state maximum observed plasma concentration (Css_max) was 111.9 ng/mL on day 14.","Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520001/),[ng] / [ml],111.9,55023,DB01156,Bupropion
,30520001,apparent oral clearance,The population pharmacokinetic model findings indicated an apparent oral clearance of 221 L/h for bupropion in a typical healthy 60.9-kg Chinese volunteer.,"Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520001/),[l] / [h],221,55024,DB01156,Bupropion
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB01156,Bupropion
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB01156,Bupropion
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB01156,Bupropion
≥,26946423,Extraction efficiency,Extraction efficiency for all analytes was ≥70%.,"Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26946423/),%,70,59094,DB01156,Bupropion
,27255113,Area under the plasma concentration-time curve from zero to infinity ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,65,61848,DB01156,Bupropion
,27255113,Area under the plasma concentration-time curve from zero to infinity ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,6,61849,DB01156,Bupropion
,27255113,Area under the plasma concentration-time curve from zero to infinity ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,4,61850,DB01156,Bupropion
,27255113,Cmax ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,35,61851,DB01156,Bupropion
,27255113,Cmax ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,6,61852,DB01156,Bupropion
,27255113,Cmax ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,3,61853,DB01156,Bupropion
,27255113,Cmax ratios,"Area under the plasma concentration-time curve from zero to infinity ratios were on average approximately 65, 6, 6, and 4 and Cmax ratios were approximately 35, 6, 3, and 0.5 for (2R,3R)-/(2S,3S)-hydroxybupropion, R-/S-bupropion, (1S,2R)-/(1R,2S)-erythrohydrobupropion, and (1R,2R)-/(1S,2S)-threohydrobupropion, respectively.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),,0.5,61854,DB01156,Bupropion
,27255113,area under the plasma concentration-time curve,"The prediction of steady-state pharmacokinetics demonstrated differential stereospecific accumulation [partial area under the plasma concentration-time curve after the final simulated bupropion dose (300-312 hours) from 185 to 37,447 nM⋅h] and elimination [terminal half-life of approximately 7-46 hours] of bupropion metabolites, which may explain observed stereoselective differences in bupropion effect and DDI risk with CYP2D6 at steady state.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),h·nM,"185 to 37,447",61855,DB01156,Bupropion
,27255113,terminal half-life,"The prediction of steady-state pharmacokinetics demonstrated differential stereospecific accumulation [partial area under the plasma concentration-time curve after the final simulated bupropion dose (300-312 hours) from 185 to 37,447 nM⋅h] and elimination [terminal half-life of approximately 7-46 hours] of bupropion metabolites, which may explain observed stereoselective differences in bupropion effect and DDI risk with CYP2D6 at steady state.",Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27255113/),h,7-46,61856,DB01156,Bupropion
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,22.48,65057,DB01156,Bupropion
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,18.34,65058,DB01156,Bupropion
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.62,65059,DB01156,Bupropion
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.68,65060,DB01156,Bupropion
,18611395,K(i),"Citral and geraniol strongly inhibited CYP2B6 hydroxylase activity in a competitive manner, with K(i) values of 6.8 and 10.3muM, respectively, which are higher than the K(i) (1.8muM) of the well-known CYP2B6-selective inhibitor thio-TEPA.",The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611395/),muM,6.8,67153,DB01156,Bupropion
,18611395,K(i),"Citral and geraniol strongly inhibited CYP2B6 hydroxylase activity in a competitive manner, with K(i) values of 6.8 and 10.3muM, respectively, which are higher than the K(i) (1.8muM) of the well-known CYP2B6-selective inhibitor thio-TEPA.",The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611395/),muM,10.3,67154,DB01156,Bupropion
,18611395,K(i),"Citral and geraniol strongly inhibited CYP2B6 hydroxylase activity in a competitive manner, with K(i) values of 6.8 and 10.3muM, respectively, which are higher than the K(i) (1.8muM) of the well-known CYP2B6-selective inhibitor thio-TEPA.",The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611395/),muM,1.8,67155,DB01156,Bupropion
,23530019,half-life of nicotine elimination,"The half-life of nicotine elimination was 33 minutes, and levels were undetectable by 4 hours.",Nicotine kinetics in zebra finches in vivo and in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),min,33,77530,DB01156,Bupropion
,23530019,brain levels,Nicotine brain levels were 30 and 14 ng/g 1 and 2 hours after treatment.,Nicotine kinetics in zebra finches in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),[ng] / [g],30,77531,DB01156,Bupropion
,23530019,brain levels,Nicotine brain levels were 30 and 14 ng/g 1 and 2 hours after treatment.,Nicotine kinetics in zebra finches in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),[ng] / [g],14,77532,DB01156,Bupropion
,23530019,Michaelis-Menten constant (K(m)),Nicotine was metabolized to cotinine with a Michaelis-Menten constant (K(m)) of 96 µM and a V(max) of 56 pmol/min per milligram.,Nicotine kinetics in zebra finches in vivo and in vitro. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),μM,96,77533,DB01156,Bupropion
,23530019,V(max),Nicotine was metabolized to cotinine with a Michaelis-Menten constant (K(m)) of 96 µM and a V(max) of 56 pmol/min per milligram.,Nicotine kinetics in zebra finches in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),[pM] / [milligram·min],56,77534,DB01156,Bupropion
,15782082,half-lives,"Relative to adults, the mean half-lives of bupropion (12.1 hours) and threohydrobupropion (26.3 hours) were significantly shorter, and areas under the concentration curve ratios of metabolites to bupropion were 19% to 80% higher.",Steady-state pharmacokinetics of bupropion SR in juvenile patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15782082/),h,12.1,84667,DB01156,Bupropion
,15782082,half-lives,"Relative to adults, the mean half-lives of bupropion (12.1 hours) and threohydrobupropion (26.3 hours) were significantly shorter, and areas under the concentration curve ratios of metabolites to bupropion were 19% to 80% higher.",Steady-state pharmacokinetics of bupropion SR in juvenile patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15782082/),h,26.3,84668,DB01156,Bupropion
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB01156,Bupropion
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB01156,Bupropion
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB01156,Bupropion
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB01156,Bupropion
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB01156,Bupropion
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,31.49,85825,DB01156,Bupropion
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,22.95,85826,DB01156,Bupropion
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,1.99,85827,DB01156,Bupropion
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,1.76,85828,DB01156,Bupropion
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,11.77,85829,DB01156,Bupropion
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,10.44,85830,DB01156,Bupropion
,28685396,relative bioavailability,The data indicates that the relative bioavailability of the ER formulations was 72.3-78.8% compared with IR 75 mg.,Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685396/),%,72.3-78.8,89079,DB01156,Bupropion
,32764875,overall,"The optimized formulation (73.3 mg xanthan, 120 mg glucomannan, 8.4 mg tamarind kernel powder, 78.3 mg HPMC K15M) was achieved with the overall desirability equals 0.782.","Promising Swellable Floating Bupropion Tablets: Formulation, in vitro/in vivo Evaluation and Comparative Pharmacokinetic Study in Human Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764875/),,0.782,93547,DB01156,Bupropion
>,25582505,extraction efficiency,"The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%.","Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582505/),%,90.5,101195,DB01156,Bupropion
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,6.7,104991,DB01156,Bupropion
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,0.13,104992,DB01156,Bupropion
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB01156,Bupropion
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB01156,Bupropion
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB01156,Bupropion
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB01156,Bupropion
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB01156,Bupropion
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB01156,Bupropion
,23047502,AUC 0-infinity ratio,"The corresponding values for AUC 0-infinity ratio of 4-hydroxybupropion over bupropion were 1.28 (0.811, 1.014).",The effects of sodium ferulate on the pharmacokinetics of bupropion and its active metabolite in healthy men. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047502/),,1.28,124914,DB01156,Bupropion
,31587004,oral bioavailability,"Subsequently, pharmacokinetic study showed that the oral bioavailability of WZ35 is 10.56%.",Cytochrome P450-Mediated Metabolic Characterization of a Mono-Carbonyl Curcumin Analog WZ35. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587004/),%,10.56,135697,DB01156,Bupropion
,8786247,CL app,"Mean (+/- SD) CL app of bupropion was 1.6 +/- 0.4 L/hr/kg, approximately 80% of the corresponding value reported for younger patients.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),[l] / [h·kg],1.6,136560,DB01156,Bupropion
,8786247,t1/2,"Mean bupropion t1/2 was 34.2 +/- 8.7 hours, and average apparent Vd (Vd app) was 79.3 +/- 29.4 L/kg.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,34.2,136561,DB01156,Bupropion
,8786247,apparent Vd (Vd app),"Mean bupropion t1/2 was 34.2 +/- 8.7 hours, and average apparent Vd (Vd app) was 79.3 +/- 29.4 L/kg.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),[l] / [kg],79.3,136562,DB01156,Bupropion
,8786247,Apparent half-lives (t1/2 app),"Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,34.2,136563,DB01156,Bupropion
,8786247,Apparent half-lives (t1/2 app),"Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,61.4,136564,DB01156,Bupropion
,8786247,Apparent half-lives (t1/2 app),"Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,38.8,136565,DB01156,Bupropion
,21053991,elimination half-life,"Consistent with an elimination half-life of ∼24 hours, steady-state conditions are reached within 4 days of repeat dosing.",A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053991/),h,∼24,138379,DB01156,Bupropion
,20102294,area under the concentration versus time curve,St. John's wort treatment decreased the area under the concentration versus time curve extrapolated to infinity of bupropion in healthy volunteers from 1.4 microg.h ml(-1) (95% confidence interval [CI] = 1.2-1.6 microg.h ml(-1)) after bupropion alone to 1.2 microg.h ml(-1) (95% CI = 1.1-1.3 microg.h ml(-1)) during St. John's wort treatment.,Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102294/),[h·μg] / [ml],1.4,148047,DB01156,Bupropion
,20102294,area under the concentration versus time curve,St. John's wort treatment decreased the area under the concentration versus time curve extrapolated to infinity of bupropion in healthy volunteers from 1.4 microg.h ml(-1) (95% confidence interval [CI] = 1.2-1.6 microg.h ml(-1)) after bupropion alone to 1.2 microg.h ml(-1) (95% CI = 1.1-1.3 microg.h ml(-1)) during St. John's wort treatment.,Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102294/),[h·μg] / [ml],1.2,148048,DB01156,Bupropion
,20102294,oral clearance,St. John's wort treatment increased the oral clearance of bupropion from 108.3 l h(-1) (95% CI = 95.4-123.0 l h(-1)) to 130.0 l h(-1) (95% CI = 118.4-142.7 l h(-1)).,Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102294/),[l] / [h],108.3,148049,DB01156,Bupropion
,20102294,oral clearance,St. John's wort treatment increased the oral clearance of bupropion from 108.3 l h(-1) (95% CI = 95.4-123.0 l h(-1)) to 130.0 l h(-1) (95% CI = 118.4-142.7 l h(-1)).,Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102294/),[l] / [h],130.0,148050,DB01156,Bupropion
,20102294,half-life,St. John's wort treatment decreased the half-life of hydroxybupropion from 26.7 h (95% CI = 23.8-29.9 h) to 24.4 h (95% CI = 21.9-27.3 h).,Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102294/),h,26.7,148051,DB01156,Bupropion
,20102294,half-life,St. John's wort treatment decreased the half-life of hydroxybupropion from 26.7 h (95% CI = 23.8-29.9 h) to 24.4 h (95% CI = 21.9-27.3 h).,Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102294/),h,24.4,148052,DB01156,Bupropion
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,27,151996,DB01156,Bupropion
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,80,151997,DB01156,Bupropion
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),[μM] / [l],16,151998,DB01156,Bupropion
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,75,151999,DB01156,Bupropion
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,19.3,152000,DB01156,Bupropion
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,21.5,152001,DB01156,Bupropion
>,24186263,AUC ratio,The static model predicted in vivo interaction with predicted AUC ratio values of >1.1 for all CYP (except CYP3A4).,"Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24186263/),,1.1,154701,DB01156,Bupropion
,3932079,elimination half lives (t1/2),"After the first dose mean elimination half lives (t1/2) of bupropion, and metabolites I and II were 8, 19 and 19 h respectively.",The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932079/),h,8,155839,DB01156,Bupropion
,3932079,elimination half lives (t1/2),"After the first dose mean elimination half lives (t1/2) of bupropion, and metabolites I and II were 8, 19 and 19 h respectively.",The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932079/),h,19,155840,DB01156,Bupropion
,3932079,t1/2,Accumulation of I was consistent with its rate of elimination after single doses while that of II was greater than predicted with prolongation of t1/2 to 35 h.,The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932079/),h,35,155841,DB01156,Bupropion
,3932079,half life,Metabolite III was barely detectable after single doses but its accumulation on multiple dosing was consistent with its long half life (35 h) determined on occasion 2.,The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932079/),h,35,155842,DB01156,Bupropion
,25097227,clearance,"Relative to the postpartum period, the average midpregnancy clearance of BUP trended higher (3.6 ± 0.15 versus 2.7 ± 0.28 l/h per kg) and the average C(max) (294 ± 91 versus 361 ± 64 ng/ml) and the area under the curve (AUC) of BUP values (288 ± 22 versus 382 ± 42 h·ng/ml) trended lower.",Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[l] / [h·kg],3.6,164349,DB01156,Bupropion
,25097227,clearance,"Relative to the postpartum period, the average midpregnancy clearance of BUP trended higher (3.6 ± 0.15 versus 2.7 ± 0.28 l/h per kg) and the average C(max) (294 ± 91 versus 361 ± 64 ng/ml) and the area under the curve (AUC) of BUP values (288 ± 22 versus 382 ± 42 h·ng/ml) trended lower.",Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[l] / [h·kg],2.7,164350,DB01156,Bupropion
,25097227,C(max),"Relative to the postpartum period, the average midpregnancy clearance of BUP trended higher (3.6 ± 0.15 versus 2.7 ± 0.28 l/h per kg) and the average C(max) (294 ± 91 versus 361 ± 64 ng/ml) and the area under the curve (AUC) of BUP values (288 ± 22 versus 382 ± 42 h·ng/ml) trended lower.",Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[ng] / [ml],294,164351,DB01156,Bupropion
,25097227,C(max),"Relative to the postpartum period, the average midpregnancy clearance of BUP trended higher (3.6 ± 0.15 versus 2.7 ± 0.28 l/h per kg) and the average C(max) (294 ± 91 versus 361 ± 64 ng/ml) and the area under the curve (AUC) of BUP values (288 ± 22 versus 382 ± 42 h·ng/ml) trended lower.",Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[ng] / [ml],361,164352,DB01156,Bupropion
,25097227,area under the curve (AUC),"Relative to the postpartum period, the average midpregnancy clearance of BUP trended higher (3.6 ± 0.15 versus 2.7 ± 0.28 l/h per kg) and the average C(max) (294 ± 91 versus 361 ± 64 ng/ml) and the area under the curve (AUC) of BUP values (288 ± 22 versus 382 ± 42 h·ng/ml) trended lower.",Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[h·ng] / [ml],288,164353,DB01156,Bupropion
,25097227,area under the curve (AUC),"Relative to the postpartum period, the average midpregnancy clearance of BUP trended higher (3.6 ± 0.15 versus 2.7 ± 0.28 l/h per kg) and the average C(max) (294 ± 91 versus 361 ± 64 ng/ml) and the area under the curve (AUC) of BUP values (288 ± 22 versus 382 ± 42 h·ng/ml) trended lower.",Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[h·ng] / [ml],382,164354,DB01156,Bupropion
,25097227,AUC(,AUC(OH-BUP) also tended to be lower midpregnancy compared with postpartum (194 ± 76 versus 353 ± 165 h·ng/ml).,Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[h·ng] / [ml],194,164355,DB01156,Bupropion
,25097227,AUC(,AUC(OH-BUP) also tended to be lower midpregnancy compared with postpartum (194 ± 76 versus 353 ± 165 h·ng/ml).,Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25097227/),[h·ng] / [ml],353,164356,DB01156,Bupropion
,19694739,AUC(0-infinity),"Bupropion mean AUC(0-infinity) value was 1.4 microg.h ml(-1)[95% confidence interval (CI) 1.2, 1.6] prior to G. biloba treatment and 1.2 microg.h ml(-1) (95% CI 1.1, 1.4) after 14 days of treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],1.4,164437,DB01156,Bupropion
,19694739,AUC(0-infinity),"Bupropion mean AUC(0-infinity) value was 1.4 microg.h ml(-1)[95% confidence interval (CI) 1.2, 1.6] prior to G. biloba treatment and 1.2 microg.h ml(-1) (95% CI 1.1, 1.4) after 14 days of treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],1.2,164438,DB01156,Bupropion
,19694739,AUC(0-infinity),"Hydroxybupropion mean AUC(0-infinity) value was 8.2 microg.h ml(-1) (95% CI 6.5, 10.4) before G. biloba administration and 8.7 microg.h ml(-1) (95% CI 7.1, 10.6) after treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],8.2,164439,DB01156,Bupropion
,19694739,AUC(0-infinity),"Hydroxybupropion mean AUC(0-infinity) value was 8.2 microg.h ml(-1) (95% CI 6.5, 10.4) before G. biloba administration and 8.7 microg.h ml(-1) (95% CI 7.1, 10.6) after treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],8.7,164440,DB01156,Bupropion
,19694739,C(max),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[ng] / [ml],221.8,164441,DB01156,Bupropion
,19694739,C(max),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[ng] / [ml],272.7,164442,DB01156,Bupropion
,19694739,t(1/2),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),h,25.0,164443,DB01156,Bupropion
,19694739,t(1/2),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),h,21.9,164444,DB01156,Bupropion
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],15.371,167278,DB01156,Bupropion
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],6.901,167279,DB01156,Bupropion
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,8.751,167280,DB01156,Bupropion
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.032,167281,DB01156,Bupropion
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.88,167282,DB01156,Bupropion
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.602,167283,DB01156,Bupropion
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.2,167284,DB01156,Bupropion
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,1.95,167285,DB01156,Bupropion
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.038,167286,DB01156,Bupropion
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.107,167287,DB01156,Bupropion
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.212,167288,DB01156,Bupropion
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.567,167289,DB01156,Bupropion
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.853,167290,DB01156,Bupropion
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.422,167291,DB01156,Bupropion
,29189941,terminal half-life,"The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing.",Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189941/),h,66,169321,DB01156,Bupropion
,29189941,absolute oral bioavailability,The mean absolute oral bioavailability of vortioxetine is 75%.,Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189941/),%,75,169322,DB01156,Bupropion
,20876786,AUC ratio,"Among the CYP2B6*6 carriers (n = 13), the NR1I2 TGT (-25385T + g.7635G + g.8055T) carriers exhibited a significantly lower AUC ratio, representing the CYP2B6 hydroxylation activity, compared with the TGT noncarriers, in the induced state (11.9 versus 20.3, p = 0.045).",Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876786/),,11.9,169327,DB01156,Bupropion
,20876786,AUC ratio,"Among the CYP2B6*6 carriers (n = 13), the NR1I2 TGT (-25385T + g.7635G + g.8055T) carriers exhibited a significantly lower AUC ratio, representing the CYP2B6 hydroxylation activity, compared with the TGT noncarriers, in the induced state (11.9 versus 20.3, p = 0.045).",Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876786/),,20.3,169328,DB01156,Bupropion
,3936237,half-life,"BUP half-life in pH 7.4 plasma stored at 22 and 37 degrees C was 54.2 and 11.4 h, respectively.",Stability of bupropion and its major metabolites in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3936237/),h,54.2,182753,DB01156,Bupropion
,3936237,half-life,"BUP half-life in pH 7.4 plasma stored at 22 and 37 degrees C was 54.2 and 11.4 h, respectively.",Stability of bupropion and its major metabolites in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3936237/),h,11.4,182754,DB01156,Bupropion
,21656534,resolution factor,"The chromatographic separation of the analytes was achieved on a Zorbax Eclipse XDB C(18) (150 × 4.6 mm, 5 µm) analytical column using isocratic mobile phase consisting of 20 mm ammonium acetate-methanol (10:90, v/v), with a resolution factor of 3.5.","Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656534/),,3.5,182922,DB01156,Bupropion
,21656534,process efficiency,"The matrix effect was assessed by post-column infusion and the mean process efficiency was 96.08 and 94.40% for BUP and HBUP, respectively.","Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656534/),%,96.08,182923,DB01156,Bupropion
,21656534,process efficiency,"The matrix effect was assessed by post-column infusion and the mean process efficiency was 96.08 and 94.40% for BUP and HBUP, respectively.","Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656534/),%,94.40,182924,DB01156,Bupropion
,27435752,Racc,"Finally, the model was refined to incorporate the fractional contribution of enzymes, including CYP2B6, propagating autoinduction into the model (Racc 1.7 vs. 1.7 observed).",Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435752/),,1.7,183894,DB01156,Bupropion
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],1.67,189481,DB01156,Bupropion
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],3.80,189482,DB01156,Bupropion
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],0.68,189483,DB01156,Bupropion
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],1.13,189484,DB01156,Bupropion
,12972093,relative bioavailability,"The relative bioavailability of the ST was (99.1+/-1.51)%, the results of ANOVA and two one sided tests indicated that the new ST exhibited good sustained release properties and was bioequivalent to the RT.",HPLC determination and pharmacokinetics of sustained-release bupropion tablets in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12972093/),%,99.1,192969,DB01156,Bupropion
,26916207,steady-state brain extracellular fluid/plasma unbound concentration ratio,"The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry.","Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26916207/),,1.9,196043,DB01156,Bupropion
,26916207,steady-state brain extracellular fluid/plasma unbound concentration ratio,"The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry.","Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26916207/),,1.7,196044,DB01156,Bupropion
,25187485,AUC,"The mean bupropion AUC was 771 versus 670 hours⋅ng/ml in individuals with and without CYP2C19*2, respectively (P = 0.017).",Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25187485/),[h·ng] / [ml],771,211797,DB01156,Bupropion
,25187485,AUC,"The mean bupropion AUC was 771 versus 670 hours⋅ng/ml in individuals with and without CYP2C19*2, respectively (P = 0.017).",Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25187485/),[h·ng] / [ml],670,211798,DB01156,Bupropion
,29079874,t 1/2,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,67,216604,DB01156,Bupropion
,29079874,t max,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,5,216605,DB01156,Bupropion
,29079874,volume of distribution (V d/F,Large volume of distribution (V d/F = 102 L/kg) indicated its penetration into peripheral compartments.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],102,216606,DB01156,Bupropion
,29079874,C max,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,60,216607,DB01156,Bupropion
,29079874,volume of distribution (V d/F,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],32.2,216608,DB01156,Bupropion
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,19,216609,DB01156,Bupropion
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,7.5,216610,DB01156,Bupropion
,29079874,IC 50,"EMD386088 did not influence on CYP3A4 activity, and it has been classified as a very weak CYP2D6 inhibitor (IC 50 = 2.25 μM).","Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),μM,2.25,216611,DB01156,Bupropion
,16815319,apparent clearance,"Rifampin treatment increased the apparent clearance of bupropion in Chinese subjects and white subjects combined (n = 16) from 2.6 L x h(-1) x kg(-1) (95% confidence interval [CI], 2.3-3.0 L x h(-1) x kg(-1)) after bupropion alone to 7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1)) during rifampin treatment.",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[l] / [h·kg],2.6,216852,DB01156,Bupropion
,16815319,apparent clearance,"Rifampin treatment increased the apparent clearance of bupropion in Chinese subjects and white subjects combined (n = 16) from 2.6 L x h(-1) x kg(-1) (95% confidence interval [CI], 2.3-3.0 L x h(-1) x kg(-1)) after bupropion alone to 7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1)) during rifampin treatment.",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[l] / [h·kg],7.9,216853,DB01156,Bupropion
,16815319,half-life,"Rifampin treatment decreased the half-life of bupropion from 15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,15.9,216854,DB01156,Bupropion
,16815319,half-life,"Rifampin treatment decreased the half-life of bupropion from 15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,8.2,216855,DB01156,Bupropion
,16815319,maximum concentration,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[ng] / [ml],395,216856,DB01156,Bupropion
,16815319,maximum concentration,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[ng] / [ml],548,216857,DB01156,Bupropion
,16815319,area under the concentration-time curve,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[h·μg] / [ml],14.7,216858,DB01156,Bupropion
,16815319,area under the concentration-time curve,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[h·μg] / [ml],8.4,216859,DB01156,Bupropion
,16815319,elimination half-life,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,21.9,216860,DB01156,Bupropion
,16815319,elimination half-life,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,10.7,216861,DB01156,Bupropion
,25835223,drug loading efficiency,"The optimized nanoparticles showed particle size of 320 ± 90 nm with polydispersity index of 0.85, the zeta potential of -29.6 mV, drug loading efficiency of 43.1 ± 0.28% and release efficiency of 66.7 ± 2%.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),%,43.1,217821,DB01156,Bupropion
,25835223,release efficiency,"The optimized nanoparticles showed particle size of 320 ± 90 nm with polydispersity index of 0.85, the zeta potential of -29.6 mV, drug loading efficiency of 43.1 ± 0.28% and release efficiency of 66.7 ± 2%.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),%,66.7,217822,DB01156,Bupropion
,25835223,area under the serum concentration-time profile,"The area under the serum concentration-time profile for the pulmonary nanospheres versus simple solution was 10 237.84 versus 28.8 µg/ml min, Tmax of 360 versus 60 min and the Cmax of 1927.93 versus9.93 ng/ml, respectively.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),[μg] / [min·ml],10 237.84,217823,DB01156,Bupropion
,25835223,area under the serum concentration-time profile,"The area under the serum concentration-time profile for the pulmonary nanospheres versus simple solution was 10 237.84 versus 28.8 µg/ml min, Tmax of 360 versus 60 min and the Cmax of 1927.93 versus9.93 ng/ml, respectively.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),[μg] / [min·ml],28.8,217824,DB01156,Bupropion
,25835223,Tmax,"The area under the serum concentration-time profile for the pulmonary nanospheres versus simple solution was 10 237.84 versus 28.8 µg/ml min, Tmax of 360 versus 60 min and the Cmax of 1927.93 versus9.93 ng/ml, respectively.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),min,360,217825,DB01156,Bupropion
,25835223,Tmax,"The area under the serum concentration-time profile for the pulmonary nanospheres versus simple solution was 10 237.84 versus 28.8 µg/ml min, Tmax of 360 versus 60 min and the Cmax of 1927.93 versus9.93 ng/ml, respectively.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),min,60,217826,DB01156,Bupropion
,25835223,Cmax,"The area under the serum concentration-time profile for the pulmonary nanospheres versus simple solution was 10 237.84 versus 28.8 µg/ml min, Tmax of 360 versus 60 min and the Cmax of 1927.93 versus9.93 ng/ml, respectively.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),[ng] / [ml],1927.93,217827,DB01156,Bupropion
,25835223,Cmax,"The area under the serum concentration-time profile for the pulmonary nanospheres versus simple solution was 10 237.84 versus 28.8 µg/ml min, Tmax of 360 versus 60 min and the Cmax of 1927.93 versus9.93 ng/ml, respectively.",In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),[ng] / [ml],9.93,217828,DB01156,Bupropion
,25835223,absolute bioavailability,The absolute bioavailability of the drug was 86.69% for nanospheres and 0.25% for pulmonary simple solution.,In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),%,86.69,217829,DB01156,Bupropion
,25835223,absolute bioavailability,The absolute bioavailability of the drug was 86.69% for nanospheres and 0.25% for pulmonary simple solution.,In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835223/),%,0.25,217830,DB01156,Bupropion
,6785419,Peak plasma bupropion levels,"Peak plasma bupropion levels after oral dosing were highly variable, ranging from 12.9 to 63.5 ng ml-1 at 26 to 32 min after drug administration.",Radioimmunoassay and pharmacokinetic profile of bupropion in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6785419/),[ng] / [ml],12.9 to 63.5,220112,DB01156,Bupropion
,6785419,terminal phase half-life,The mean terminal phase half-life of bupropion was calculated to be 1.73 hr after either route and the absolute oral bioavailability of the drug varied from 2.0 to 6.5%.,Radioimmunoassay and pharmacokinetic profile of bupropion in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6785419/),h,1.73,220113,DB01156,Bupropion
,6785419,absolute oral bioavailability,The mean terminal phase half-life of bupropion was calculated to be 1.73 hr after either route and the absolute oral bioavailability of the drug varied from 2.0 to 6.5%.,Radioimmunoassay and pharmacokinetic profile of bupropion in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6785419/),%,2.0 to 6.5,220114,DB01156,Bupropion
less,32738202,Ki,The Ki values in this study were less than 8.32 μM.,Evaluation of acacetin inhibition potential against cytochrome P450 in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738202/),μM,8.32,223492,DB01156,Bupropion
,8477117,peak bupropion breast milk concentration,"After a 100-mg dose, the peak bupropion breast milk concentration measured at two hours was 0.189 micrograms/mL.",Excretion of bupropion in breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477117/),[μg] / [ml],0.189,223528,DB01156,Bupropion
,8477117,Milk-to-plasma ratios,Milk-to-plasma ratios ranged from 2.51 to 8.58 over a six-hour interval.,Excretion of bupropion in breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477117/),,2.51,223529,DB01156,Bupropion
,8477117,Milk-to-plasma ratios,Milk-to-plasma ratios ranged from 2.51 to 8.58 over a six-hour interval.,Excretion of bupropion in breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477117/),,8.58,223530,DB01156,Bupropion
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],4.58,224633,DB01156,Bupropion
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],60.95,224634,DB01156,Bupropion
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],48.79,224635,DB01156,Bupropion
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],3.01,224636,DB01156,Bupropion
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],41.68,224637,DB01156,Bupropion
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],37.28,224638,DB01156,Bupropion
,22312695,flow rate,"After addition of carbamazepine as internal standard (IS) and precipitation of protein with acetonitrile, the plasma samples were analyzed on an Agilent Zorbax SB-C18 (2.1 mm x 50 mm, 3.5 microm) column at 30 degrees C, with acetonitrile-0.1% formic acid as mobile phase at a flow rate of 0.4 mL min(-1).",Determination of bupropion and its main metabolite in rat plasma by LC-MS and its application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22312695/),[ml] / [min],0.4,229028,DB01156,Bupropion
,23840296,AUC ratio,"AUC ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.5±2.1 versus 14.5±3.3 and 20.6±1.1, and 8873±1431 versus 14,504±2218 and 17,586±1046) in the induced states.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,7.5,233465,DB01156,Bupropion
,23840296,AUC ratio,"AUC ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.5±2.1 versus 14.5±3.3 and 20.6±1.1, and 8873±1431 versus 14,504±2218 and 17,586±1046) in the induced states.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,14.5,233466,DB01156,Bupropion
,23840296,AUC_hyd,"AUC ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.5±2.1 versus 14.5±3.3 and 20.6±1.1, and 8873±1431 versus 14,504±2218 and 17,586±1046) in the induced states.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,20.6,233467,DB01156,Bupropion
,23840296,AUC_hyd,"AUC ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.5±2.1 versus 14.5±3.3 and 20.6±1.1, and 8873±1431 versus 14,504±2218 and 17,586±1046) in the induced states.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,8873,233468,DB01156,Bupropion
,23840296,AUC_hyd,"AUC ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.5±2.1 versus 14.5±3.3 and 20.6±1.1, and 8873±1431 versus 14,504±2218 and 17,586±1046) in the induced states.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,"14,504",233469,DB01156,Bupropion
,23840296,AUC_hyd,"AUC ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.5±2.1 versus 14.5±3.3 and 20.6±1.1, and 8873±1431 versus 14,504±2218 and 17,586±1046) in the induced states.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,"17,586",233470,DB01156,Bupropion
,23840296,AUC ratio,"NR1I2 TGT haplotype (-25385T+g.7635G+g.8055T) carriers exhibited a significantly decreased AUC ratio, compared with TGT noncarriers, in the basal states (7.6±1.0 versus 9.7±1.0), while this result wasn't observed in CYP2B6*6 noncarriers.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,7.6,233471,DB01156,Bupropion
,23840296,AUC ratio,"NR1I2 TGT haplotype (-25385T+g.7635G+g.8055T) carriers exhibited a significantly decreased AUC ratio, compared with TGT noncarriers, in the basal states (7.6±1.0 versus 9.7±1.0), while this result wasn't observed in CYP2B6*6 noncarriers.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,9.7,233472,DB01156,Bupropion
,23840296,AUC ratio,"Moreover, individuals with complete mutation-type [CYP2B6*6/*6+NR1I2 TGT+ -24113AA+ -24020 (-)/(-)] showed even lower percent difference of AUC ratio (8.7±1.2 versus 39.5±8.2) than those with complete wild-type.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,8.7,233473,DB01156,Bupropion
,23840296,AUC ratio,"Moreover, individuals with complete mutation-type [CYP2B6*6/*6+NR1I2 TGT+ -24113AA+ -24020 (-)/(-)] showed even lower percent difference of AUC ratio (8.7±1.2 versus 39.5±8.2) than those with complete wild-type.",Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840296/),,39.5,233474,DB01156,Bupropion
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],3.64,234498,DB01156,Bupropion
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],25.5,234499,DB01156,Bupropion
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB01156,Bupropion
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB01156,Bupropion
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB01156,Bupropion
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB01156,Bupropion
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB01156,Bupropion
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB01156,Bupropion
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB01156,Bupropion
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB01156,Bupropion
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB01156,Bupropion
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB01156,Bupropion
greater,17167747,Overall extraction recovery,Overall extraction recovery of hydroxybupropion enantiomers and the internal standard phenacetin from plasma was greater than 80% and reproducible over the concentration range of 12.5-500 ng/ml for each enantiomer.,Stereoselective analysis of hydroxybupropion and application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17167747/),%,80,238584,DB01156,Bupropion
,9378846,area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[h·ng] / [ml],"1,164",241574,DB01156,Bupropion
,9378846,maximum concentration (Cmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[h·ng] / [ml],"1,161",241575,DB01156,Bupropion
,9378846,maximum concentration (Cmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[ng] / [ml],144,241576,DB01156,Bupropion
,9378846,maximum concentration (Cmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[ng] / [ml],143,241577,DB01156,Bupropion
,9378846,maximum concentration (Cmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),h,3.00,241578,DB01156,Bupropion
,9378846,time to reach Cmax (tmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[h·ng] / [ml],"1,161",241579,DB01156,Bupropion
,9378846,time to reach Cmax (tmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[ng] / [ml],144,241580,DB01156,Bupropion
,9378846,time to reach Cmax (tmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),[ng] / [ml],143,241581,DB01156,Bupropion
,9378846,time to reach Cmax (tmax),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),h,3.00,241582,DB01156,Bupropion
,9378846,half-life (t1/2),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),h,2.88,241583,DB01156,Bupropion
,9378846,half-life (t1/2),"Mean (+/-SD) values of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity), maximum concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2) of bupropion in smokers and nonsmokers, respectively, were 1,164 +/- 220 ng.hr/mL and 1,161 +/- 292 ng.hr/mL; 144 +/- 28 ng/mL and 143 +/- 39 ng/mL; 3.00 +/- 0.50 hours and 2.88 +/- 0.49 hours; and 19 +/- 5 hours and 18 +/- 3 hours.",Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378846/),h,19,241584,DB01156,Bupropion
,17135996,area under the curve ratios,Mean 24-hour area under the curve ratios of metabolites to bupropion ranged from 1.0 for erythrohydrobupropion to 16.4 for hydroxybupropion.,Steady-state clinical pharmacokinetics of bupropion extended-release in youths. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17135996/),,1.0,242035,DB01156,Bupropion
,17135996,area under the curve ratios,Mean 24-hour area under the curve ratios of metabolites to bupropion ranged from 1.0 for erythrohydrobupropion to 16.4 for hydroxybupropion.,Steady-state clinical pharmacokinetics of bupropion extended-release in youths. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17135996/),,16.4,242036,DB01156,Bupropion
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,83.2,244934,DB01156,Bupropion
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,106.1,244935,DB01156,Bupropion
,11452710,ratio of hydro,"The mean ratio of hydroxybupropion to bupropion AUC for adolescents was approximately 4 to 5, which is lower than that previously reported for adults.",Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452710/),,4 to 5,249767,DB01156,Bupropion
,6804243,disposition half-lives,Mean disposition half-lives across treatments were 1.2-1.4 h for t1/2 alpha and 10.7-13.8 h for the t1/2 beta.,"Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804243/),h,1.2-1.4,261168,DB01156,Bupropion
,6804243,t1/2 alpha,Mean disposition half-lives across treatments were 1.2-1.4 h for t1/2 alpha and 10.7-13.8 h for the t1/2 beta.,"Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804243/),h,1.2-1.4,261169,DB01156,Bupropion
,6804243,t1/2 beta,Mean disposition half-lives across treatments were 1.2-1.4 h for t1/2 alpha and 10.7-13.8 h for the t1/2 beta.,"Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804243/),h,10.7-13.8,261170,DB01156,Bupropion
,12607628,elimination half-life,BP is rapidly absorbed after oral administration and demonstrates biphasic elimination with an elimination half-life of 11 - 14 hours.,Bupropion: pharmacological and clinical profile in smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607628/),h,11 - 14,271070,DB01156,Bupropion
,6406470,half-life,The half-life of the initial (alpha) phase is approximately 1.5 hours and that of the second (beta) phase is approximately 14.0 hours.,Clinical pharmacokinetics of bupropion: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406470/),h,1.5,272090,DB01156,Bupropion
,6406470,half-life,The half-life of the initial (alpha) phase is approximately 1.5 hours and that of the second (beta) phase is approximately 14.0 hours.,Clinical pharmacokinetics of bupropion: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406470/),h,14.0,272091,DB01156,Bupropion
,6406470,ratio between plasma clearance and,The ratio between plasma clearance and fraction absorbed (approximately 2 L/hr/kg) is consistent within the 50-250 mg single dose range.,Clinical pharmacokinetics of bupropion: a review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406470/),[l] / [h·kg],2,272092,DB01156,Bupropion
,6406470,fraction absorbed,The ratio between plasma clearance and fraction absorbed (approximately 2 L/hr/kg) is consistent within the 50-250 mg single dose range.,Clinical pharmacokinetics of bupropion: a review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406470/),[l] / [h·kg],2,272093,DB01156,Bupropion
